{"id":11018,"date":"2020-08-19T10:42:22","date_gmt":"2020-08-19T14:42:22","guid":{"rendered":"http:\/\/www.drugpatentwatch.com\/blog\/?p=11018"},"modified":"2026-03-30T09:16:51","modified_gmt":"2026-03-30T13:16:51","slug":"investing-in-drug-companies-here-are-vital-non-patent-factors-to-consider","status":"publish","type":"post","link":"https:\/\/www.drugpatentwatch.com\/blog\/investing-in-drug-companies-here-are-vital-non-patent-factors-to-consider\/","title":{"rendered":"What Actually Drives Pharma Returns: 10 Non-Patent Factors Every Investor Needs to Model"},"content":{"rendered":"\n

Why Patents Are the Wrong Starting Point<\/h2>\n\n\n\n
\"\"<\/figure>\n\n\n\n

Most analysts open a pharma investment thesis by pulling Orange Book listings and counting years until the next Paragraph IV challenge. That is a reasonable starting point. It is a poor finishing point.<\/p>\n\n\n\n

A compound can hold a clean, unchallenged composition-of-matter patent through 2031 and still generate near-zero returns if the drug’s payer coverage is restricted to second-line therapy, if a Phase III readout collapse cuts market cap by 60% overnight, or if a biosimilar interchangeability designation accelerates reference product erosion two years ahead of the formal patent expiry.<\/p>\n\n\n\n

Conversely, a drug with a patent portfolio that looks soft on paper can outperform if the manufacturer holds orphan drug exclusivity, a PDUFA priority review voucher, and a durable formulary position backed by outcomes-based contracts at the three largest PBMs. These are the factors that patent databases do not directly surface.<\/p>\n\n\n\n

This pillar page covers ten of them in enough technical depth that portfolio managers, IP teams, and R&D leads can build them directly into valuation models, competitive response playbooks, and due diligence checklists. The structure follows the actual decision sequence: from regulatory moats and market access mechanics, through clinical risk and management quality, to the macro political layer that is now repricing entire therapeutic categories.<\/p>\n\n\n\n

\n\n\n\n

Regulatory Exclusivity: The Non-Patent Moat Stack<\/h2>\n\n\n\n

Patent protection and regulatory exclusivity are legally distinct. They interact, overlap, and in some configurations run in parallel, which means a drug can retain market exclusivity well past its last Orange Book patent. Understanding this stack is the first analytical task for any pharma investment or competitive response team.<\/p>\n\n\n\n

Orphan Drug Designation: The Seven-Year Non-Patent Wall<\/strong><\/h3>\n\n\n\n

The Orphan Drug Act grants seven years of market exclusivity in the United States for drugs targeting diseases affecting fewer than 200,000 Americans. In the EU, the threshold is five in 10,000 persons in the population, and the exclusivity period runs ten years, extendable to twelve for pediatric studies. Neither period is conditional on the existence of a patent.<\/p>\n\n\n\n

The IP valuation implications are material. A drug like imatinib (Gleevec) earned orphan designation for chronic myeloid leukemia before the market widened; later indication expansions captured additional orphan exclusivities for distinct diseases. The financial architecture of a mature orphan drug franchise, therefore, includes layered exclusivity periods across indications, which makes the consolidated market exclusivity timeline significantly longer than any single patent or orphan grant suggests.<\/p>\n\n\n\n

Analysts modeling orphan-designated compounds need to map each indication separately: the disease prevalence threshold that qualified the designation, the filing date, and whether any pediatric extensions or subsequent re-designations are on record. The FDA’s Orphan Drug Product Designation Database is the primary source; the EMA’s equivalent is the Committee for Orphan Medicinal Products (COMP) registry.<\/p>\n\n\n\n

From a competitive strategy perspective, a generic or biosimilar manufacturer targeting an orphan drug cannot rely solely on patent expiry. It must wait out the full orphan exclusivity period unless it can demonstrate its product is clinically superior, a standard that requires comparative clinical evidence and is difficult to meet without expensive head-to-head trials.<\/p>\n\n\n\n

IP Valuation Note: Orphan-designated drugs command royalty rates in licensing transactions that run 10-15% higher than comparable small-molecule assets without orphan status, reflecting the non-patent exclusivity floor. When discounting cash flows in a DCF model, the orphan exclusivity period reduces the probability-weighted generic entry scenario, which mechanically increases net present value at any given discount rate.<\/strong><\/p>\n\n\n\n

505(b)(2): The Reformulation Moat and Its Evergreening Mechanics<\/strong><\/h3>\n\n\n\n

The 505(b)(2) NDA pathway allows an applicant to rely on existing safety and efficacy data from a previously approved drug while introducing a modification that creates a new, independently protectable product. The clinical and commercial logic is straightforward: shorter development timelines, lower Phase III costs, and a fresh three-year exclusivity grant on the new clinical studies, irrespective of the underlying compound’s patent status.<\/p>\n\n\n\n

The evergreening application of 505(b)(2) is where it gets strategically interesting for IP teams. A branded manufacturer facing Paragraph IV challenges on a core composition-of-matter patent can file a 505(b)(2) for an extended-release formulation, an abuse-deterrent formulation, or a fixed-dose combination, obtain new Orange Book listings on the new product, and shift commercial focus there before generic entry on the original formulation. This is the standard playbook for many CNS and opioid analgesic franchises.<\/p>\n\n\n\n

The technology roadmap for 505(b)(2) evergreening typically runs through four phases. First, the manufacturer identifies the modification class most likely to generate clinical differentiation evidence, not merely regulatory novelty, because differentiation evidence is what drives formulary adoption of the reformulated product. Second, it runs the clinical package (usually one or two bioequivalence or superiority studies) to support the 505(b)(2) submission. Third, it engineers the IP estate around the new product: new use claims, formulation claims, and method-of-treatment claims. Fourth, it executes a commercial transition that moves prescribing volume to the reformulated product before generic entry on the original, often supported by patient assistance programs and co-pay cards that make the older generic economically unattractive for patients at the pharmacy counter.<\/p>\n\n\n\n

Investors evaluating a company’s 505(b)(2) pipeline should look specifically at whether the reformulation addresses a genuine clinical limitation of the original (improved absorption, reduced food effect, lower pill burden) or is a purely defensive filing. The former generates its own demand; the latter depends entirely on commercial execution of the transition.<\/p>\n\n\n\n

Investment Strategy: Companies with active 505(b)(2) programs in high-volume oral solid-dosage therapeutic areas (CNS, cardiovascular, metabolic disease) can extend effective franchise life by four to seven years when the reformulation carries meaningful clinical differentiation. Model the 505(b)(2) product as a separate revenue line with its own peak sales trajectory and don’t assume it captures 100% of the original brand’s volume. Realistic transition rates under managed care formulary management run 40-70%, depending on whether the PBM tier placement of the reformulation matches the original’s tier positioning.<\/strong><\/p>\n\n\n\n

Biosimilars: Reference Product Exclusivity, Interchangeability, and the 12-Year Clock<\/strong><\/h3>\n\n\n\n

For biologics, regulatory exclusivity takes a different form. Under the Biologics Price Competition and Innovation Act (BPCIA), reference biologic products receive 12 years of exclusivity from the date of first licensure in the United States before any biosimilar can be approved (with a four-year data exclusivity bar on filing). The EU runs a ten-year data exclusivity period. These exclusivities are independent of any patent protection the biologic holds.<\/p>\n\n\n\n

The biosimilar approval process at FDA involves two distinct designations that matter for investment analysis. A biosimilar designation means the product has no clinically meaningful differences from the reference in terms of safety, purity, and potency. A biosimilar interchangeability designation is a stricter standard requiring evidence that switching between the reference product and the biosimilar will not produce greater risk than continuing the reference, and this designation allows pharmacists in most states to substitute the biosimilar without prescriber intervention, the same dispensing mechanic that drives rapid generic penetration.<\/p>\n\n\n\n

The commercial impact of biosimilar interchangeability on reference product revenue is not analogous to small-molecule generic substitution. Biologics carry inherent immunogenicity concerns, and payer and provider behavior differs by therapeutic category. In high-volume, self-administered categories like adalimumab (Humira), multiple biosimilars with interchangeability designations launched into a market where PBMs had heavily negotiated rebate agreements with AbbVie, and the initial penetration rates were slower than many analysts projected, before accelerating sharply once formulary exclusions shifted. In hospital-administered oncology biologics, the substitution dynamic is more predictable and faster because purchasing decisions are made centrally by pharmacy and therapeutics committees rather than through retail dispensing.<\/p>\n\n\n\n

IP Valuation Note: The biosimilar IP landscape around a mature biologic is rarely clean. Amgen’s Enbrel (etanercept), for example, has faced biosimilar competition in Europe for years but retained U.S. market exclusivity deep into the 2020s partly because of a dense patent estate covering the manufacturing process, formulation, and device. When valuing a reference biologic, analysts need to map not just the 12-year BPCIA exclusivity but the full patent thicket, including process patents, device patents, and formulation patents that biosimilar entrants will need to design around or challenge. The ‘product patent cliff’ date and the ‘effective exclusivity end date’ are often years apart.<\/strong><\/p>\n\n\n\n

Key Takeaways: Regulatory Exclusivity<\/strong><\/h3>\n\n\n\n

Orphan drug exclusivity runs independently of patent protection and resets with each new qualifying indication. The 505(b)(2) pathway offers a structured evergreening mechanism whose commercial effectiveness depends on clinical differentiation, not just regulatory novelty. Biosimilar interchangeability is the correct technical threshold to model for reference biologic revenue erosion, not mere biosimilar approval. The 12-year BPCIA exclusivity and a biologic’s patent thicket compound to produce effective exclusivity periods that vary by eight or more years from the nominal regulatory exclusivity end date.<\/p>\n\n\n\n

\n\n\n\n

Market Access and Reimbursement: Where Approved Drugs Go to Die <\/h2>\n\n\n\n

FDA approval grants a manufacturer the legal right to sell a drug. It does not grant revenue. That requires market access, a discipline that has become as technically complex as the regulatory approval process itself and is now a primary determinant of whether an approved drug reaches its commercial potential.<\/p>\n\n\n\n

What ‘Market Access’ Actually Means in a Multi-Payer System<\/strong><\/h3>\n\n\n\n

Market access describes the totality of conditions under which a drug reaches patients at a price that supports the manufacturer’s financial model. In the United States, this involves six distinct decision layers operating simultaneously: FDA approval, payer coverage decisions, formulary tier placement, prior authorization requirements, step therapy protocols, and pharmacy channel availability.<\/p>\n\n\n\n

A drug that clears FDA approval but lands on Tier 3 or 4 formulary status at major commercial payers, faces a prior authorization requirement covering 80% of the eligible population, and sits behind a two-step fail-first protocol for cheaper generics will generate revenue well below its clinical addressable market. This is not a hypothetical scenario; it describes the actual payer response to many specialty brand launches, particularly in therapeutic areas with existing generic or biosimilar options.<\/p>\n\n\n\n

Pharmacy Benefit Managers exercise substantial structural leverage here. The three largest PBMs (Express Scripts, CVS Caremark, and OptumRx) manage pharmacy benefits for roughly half of all insured Americans. Their formulary committees evaluate new drugs against existing therapeutic alternatives on a combination of clinical evidence and net cost, meaning the rebate a manufacturer is willing to pay is a direct input into formulary tier placement. A brand that does not win favorable tier placement at these three organizations may face commercial ceiling well below Phase III peak sales projections.<\/p>\n\n\n\n

Health Technology Assessment: The Economic Evidence Requirement<\/strong><\/h3>\n\n\n\n

Outside the United States, and increasingly informing U.S. payer decisions, Health Technology Assessment (HTA) evaluates whether a new drug delivers sufficient clinical and economic value relative to existing standard of care to justify its price. The UK’s NICE uses incremental cost-effectiveness ratio (ICER) thresholds, typically GBP 20,000-30,000 per quality-adjusted life year (QALY), as the primary decision criterion. Germany’s IQWIG\/G-BA system uses a comparative clinical benefit assessment, and a finding of ‘no added benefit’ triggers reference pricing that often sets net price below the manufacturer’s target.<\/p>\n\n\n\n

For investment analysis, HTA outcomes are forward-looking indicators of net realized price. A drug entering a European market with an ICER above the relevant threshold will face either price reduction through negotiation, restricted indication approval, or managed entry agreements with outcomes-based payments. Modeling pre-HTA submission using available Phase III comparative data and public ICER inputs can yield rough probability estimates for the HTA outcome, which then feeds into net price assumptions for EU revenue projections.<\/p>\n\n\n\n

The Joint Clinical Assessment (JCA) process under the EU HTA Regulation, which became mandatory for oncology and ATMPs in January 2025 and expands to other therapeutic areas in 2028 and 2030, creates a single clinical assessment for the EU, with individual member states retaining pricing and reimbursement authority. This matters for investment modeling because it produces a single comparative clinical evidence base that all 27 member state negotiations will reference, reducing the variance in payer outcomes across markets but also creating a common point of failure if the joint assessment is unfavorable.<\/p>\n\n\n\n

The IRA’s Medicare Negotiation Mechanism: A Structural Shift in U.S. Pricing Power<\/strong><\/h3>\n\n\n\n

The Inflation Reduction Act’s drug pricing provisions introduced direct Medicare price negotiation for high-expenditure, single-source drugs lacking generic or biosimilar competition. The program is phased: ten drugs selected for the first negotiation cycle became effective in 2026, with the list expanding annually. The negotiated Maximum Fair Price caps Medicare Part D cost-sharing and limits the manufacturer’s Medicare revenue at negotiated levels.<\/p>\n\n\n\n

For portfolio managers, the IRA creates a new category of patent cliff: not the generic entry cliff, but the Medicare negotiation cliff. Drugs that have had nine years of Medicare market exclusivity for small molecules (thirteen years for biologics) without facing generic competition are eligible. This matters because manufacturers previously modeled revenue on branded drugs as a function of gross-to-net dynamics (list price minus rebates and discounts), which they controlled. Post-negotiation, a portion of that revenue is governed by a government-set price ceiling.<\/p>\n\n\n\n

The investment implication is asymmetric downside. Drugs selected for negotiation face revenue reduction certainty upon the effective date of the Maximum Fair Price. Drugs not yet selected face probability-weighted selection risk in each subsequent cycle. Analysts need to monitor CMS’s selection criteria (highest Medicare expenditure, no generic\/biosimilar competition, post-exclusivity period) and map each portfolio drug’s exposure profile accordingly.<\/p>\n\n\n\n

Outcomes-Based Contracts and Novel Payment Models<\/strong><\/h3>\n\n\n\n

Payers are deploying outcomes-based contracts with increasing frequency for high-cost specialty drugs, particularly cell and gene therapies. These agreements tie a portion of the drug’s payment to real-world clinical outcomes, measured against pre-agreed endpoints, with rebate clawbacks or payment adjustments if outcomes fall below the contractual threshold.<\/p>\n\n\n\n

For gene therapy manufacturers, outcomes-based contracts solve a genuine commercial problem: a one-time therapy with a six-figure or seven-figure price creates affordability and budget impact concerns that can block formulary access. Annualized payment structures and outcomes-based rebate arrangements allow payers to manage budget exposure while allowing manufacturers to capture long-term value if the therapy works as claimed. The contracts are, however, operationally complex, requiring multi-year patient outcome tracking infrastructure, defined outcome metrics, and legal frameworks for rebate triggers.<\/p>\n\n\n\n

Investment Strategy: Companies launching into payer environments with strong HTA headwinds or Medicare negotiation eligibility need to show credible real-world evidence (RWE) strategies, not just Phase III data, as part of their commercial case. Market access teams that start HTA submission planning 18-24 months before approval, include payer-relevant endpoints in Phase III design, and have pre-launch formulary negotiations in progress consistently outperform those that treat market access as a post-approval task. In due diligence, ask specifically: what is the drug’s ICER at list price, what formulary tier is it targeting, and what is the rebate architecture that gets it there?<\/strong><\/p>\n\n\n\n

Key Takeaways: Market Access and Reimbursement<\/strong><\/h3>\n\n\n\n

FDA approval and revenue are not the same event. PBM formulary placement, prior authorization burden, and step therapy requirements are the proximate drivers of volume, not clinical profile alone. HTA outcomes in Europe now feed a joint EU-level clinical assessment that will narrow national pricing variance from 2025 onward. The IRA’s Medicare negotiation mechanism is a structural pricing constraint on high-expenditure small molecules and biologics without competition, and it requires explicit modeling in U.S. revenue projections. Outcomes-based contracts are a commercial access tool for one-time high-cost therapies, not merely a payer cost-containment mechanism.<\/p>\n\n\n\n

\n\n\n\n

Clinical Trial Success Rates: Modeling the Actual Odds<\/h2>\n\n\n\n

The average drug candidate entering Phase I has roughly a 7.9% probability of reaching regulatory approval. For oncology compounds, that figure is closer to 5.3%. For central nervous system drugs, it drops further. These are industry averages, which means well-managed pipelines at companies with strong therapeutic area expertise outperform them, and poorly designed programs at underfunded organizations underperform them significantly.<\/p>\n\n\n\n

The analytical question for investors is not the industry average but the company-specific adjusted probability for each asset at each stage.<\/p>\n\n\n\n

Phase-by-Phase Mechanics: What Actually Kills Drugs<\/strong><\/h3>\n\n\n\n

Phase I failure is primarily safety-driven. Unexpected toxicities, poor pharmacokinetic profiles, and drug-drug interaction findings account for the majority of Phase I attrition. The success rate of approximately 47% from Phase I into Phase II looks relatively healthy because Phase I programs are generally well-designed and their population (healthy volunteers, dose-escalation designs) limits efficacy signal ambiguity.<\/p>\n\n\n\n

Phase II is where efficacy questions dominate and where the 28% success rate reflects a genuine signal problem. Many Phase II failures stem from incorrect target validation, inadequate biomarker selection, or dose selection errors that produce underpowered efficacy signals. The increasing use of adaptive trial designs, which allow protocol modifications based on pre-specified interim analyses without inflating Type I error, has improved Phase II signal clarity at some organizations, but the baseline attrition remains high.<\/p>\n\n\n\n

Phase III failure at approximately 45% attrition is the most financially damaging category. Late-stage failures in large randomized controlled trials carry costs of $200-500M or more per failed program and generate immediate, often severe market cap destruction. IQVIA’s analysis of publicly traded biopharma companies shows Phase III negative readouts produce average equity value declines of 40-60% on announcement day, with recovery timelines that depend on the breadth of the remaining pipeline.<\/p>\n\n\n\n

Importantly, Phase III failure is not random. Companies with strong Phase II designs, validated biomarkers, and pre-specified enrichment strategies for responder populations consistently show better Phase III success rates than those running broad, unselected populations without predictive biomarkers. This is the analytical distinction that separates informed pipeline valuation from multiple-of-probability arithmetic.<\/p>\n\n\n\n

Biomarker Strategy as a Pipeline Valuation Multiplier<\/strong><\/h3>\n\n\n\n

Companion diagnostic development alongside the drug program is now standard practice in oncology and is expanding into immunology and CNS. A drug with a validated companion diagnostic that enriches for clinical responders changes the Phase III probability calculus: smaller, faster trials with cleaner efficacy signals and stronger regulatory review packages.<\/p>\n\n\n\n

The IP implications are also significant. A company that holds both the drug patent and the companion diagnostic IP creates a competitive moat that generic and biosimilar manufacturers cannot replicate through the standard ANDA or biosimilar pathway. The diagnostic requires separate FDA approval (as a 510(k) or PMA device), and without it, prescribers lack the clinical framework to identify eligible patients. This diagnostic lock-in extends effective market exclusivity beyond the drug’s own patent expiration for the enriched indication.<\/p>\n\n\n\n

Investment Strategy: Analysts scoring pipeline quality should weight assets with validated companion diagnostics at a probability premium of 15-20 percentage points above Phase-matched industry averages, all else equal. The diagnostic validation data is usually available through companion device filings or publications before the Phase III drug readout, which gives sophisticated investors an early signal of trial design quality.<\/strong><\/p>\n\n\n\n

Patient Enrollment and Retention: The Operational Variable That Predicts Cost and Timeline<\/strong><\/h3>\n\n\n\n

Phase II and III trial timelines routinely slip six to eighteen months beyond original estimates, primarily because enrollment runs slower than modeled. Enrollment shortfalls are directly tied to site selection, inclusion\/exclusion criteria design, and patient retention mechanics. Companies that run decentralized clinical trial elements (remote monitoring, direct-to-patient drug delivery, electronic patient-reported outcomes) consistently show tighter enrollment timelines, particularly in rare diseases with geographically dispersed patient populations.<\/p>\n\n\n\n

For investors, delayed enrollment does not simply delay the readout; it delays the PDUFA date, delays commercial launch, delays revenue recognition, and may force an additional equity raise if the company is pre-commercial. The cash runway model for any clinical-stage company should include explicit enrollment rate sensitivity: what happens to cash runway if enrollment runs 25% below model, and does the company need a bridge financing event before the readout?<\/p>\n\n\n\n

Clinical Trial Design as a Regulatory Strategy<\/strong><\/h3>\n\n\n\n

The FDA’s Breakthrough Therapy designation, granted to drugs addressing serious conditions where preliminary clinical evidence shows substantial improvement over existing therapy, grants more intensive FDA guidance during development, potential priority review, and rolling review. The commercial value of Breakthrough designation goes beyond speed: it signals clinical differentiation that payers then use in formulary placement decisions.<\/p>\n\n\n\n

Priority Review reduces the FDA review clock from ten months to six months. This matters for revenue timing: a drug targeting a condition with high unmet need and $1B+ peak sales potential generates $80-170M in revenue per month at mature launch run rates. A four-month earlier approval translates directly to near-term revenue that affects quarterly earnings.<\/p>\n\n\n\n

Key Takeaways: Clinical Trial Success<\/strong><\/h3>\n\n\n\n

Industry-average Phase I-to-approval success rates of approximately 7.9% are the floor, not the benchmark for well-managed pipelines. Phase II failure is primarily an efficacy signal problem driven by target validation and trial design quality. Phase III failure is the most destructive event in pharmaceutical company valuation, with equity impact of 40-60% at announcement. Companion diagnostic co-development improves Phase III probability and extends effective market exclusivity. Enrollment rate sensitivity belongs in every cash runway model for pre-commercial companies.<\/p>\n\n\n\n

\n\n\n\n

Management Team Quality: The Competency Stack That Predicts Phase III Outcomes <\/h2>\n\n\n\n

Experienced pharmaceutical executives consistently outperform on Phase III success rates relative to industry averages. This is not a soft observation; it reflects measurable differences in trial design quality, regulatory submission preparation, manufacturing readiness, and commercial launch execution that compound across the development timeline.<\/p>\n\n\n\n

The Technical Track Record Audit<\/strong><\/h3>\n\n\n\n

The first analytical step in management team assessment is a technical track record review, not a resume review. Specifically: how many NDA or BLA submissions has the key regulatory team executed at this company or at prior organizations? What was the outcome rate? How many complete response letters (CRLs) did the team receive, and what were the cited deficiencies?<\/p>\n\n\n\n

CRL history is publicly available through FDA correspondence databases and company SEC filings. A team that has received multiple CRLs for manufacturing deficiencies is signaling chemistry, manufacturing, and controls (CMC) execution problems that are operationally addressable but require management attention and capital. A team with repeated CRLs for inadequate clinical data is signaling a deeper trial design problem. The distinction matters for predicting how a company’s next regulatory submission will perform.<\/p>\n\n\n\n

For biologics companies, the process validation history is particularly important. Biologics are defined by their manufacturing process; changes to fermentation conditions, purification steps, or fill-and-finish operations require comparability studies and, in some cases, new clinical data. A management team without deep biomanufacturing experience running a biologics program is a material execution risk that does not appear in financial models.<\/p>\n\n\n\n

Capital Allocation and Pipeline Prioritization<\/strong><\/h3>\n\n\n\n

The CEO and CFO’s capital allocation decisions across a portfolio are direct signals of pipeline quality assessment. A company that consistently funds assets to their Phase II readouts, terminates programs on negative data, and reallocates capital to the next-priority asset is operating disciplined portfolio management. A company that continues funding Phase II programs past negative signals because of sunk-cost reasoning, or that raises equity at distressed prices to fund a single remaining asset, is signaling execution problems.<\/p>\n\n\n\n

Board composition matters here. Boards with deep operational pharma experience (former drug developers, regulatory executives, commercial leaders) exercise more informed oversight of portfolio prioritization decisions than boards composed primarily of financial professionals or general corporate directors, who may be less equipped to independently evaluate a management team’s claim that a marginal Phase II result still supports Phase III investment.<\/p>\n\n\n\n

Business Development and Licensing Track Record<\/strong><\/h3>\n\n\n\n

For companies that grow partly through in-licensing or acquisition, the BD team’s deal sourcing and diligence track record is an asset in itself. The ability to identify pre-clinical or early clinical assets at valuations that offer upside to the acquirer, structure deal economics that preserve optionality (milestones and royalties over upfront payments), and integrate acquired programs without disrupting existing operations is a durable competitive advantage that does not show up in the IP portfolio.<\/p>\n\n\n\n

Analyze the specific terms of recent in-licensing deals: what were the upfront payments relative to Phase data quality? Were milestones structured to reduce risk at each development gate, or are they heavily backloaded? Does the royalty structure preserve meaningful economics at the peak sales scenarios the company is modeling?<\/p>\n\n\n\n

Investment Strategy: Weight management team quality most heavily for pre-Phase III assets, where execution risk is highest and the team’s decisions in the next 24 months determine whether the asset reaches approval. For late-stage or commercial-stage companies, financial execution and commercial launch competency displace scientific leadership as the primary management quality indicator. Specifically, ask: does the commercial leadership team have direct prior experience launching a drug in the same therapeutic area and pricing tier?<\/strong><\/p>\n\n\n\n

Key Takeaways: Management Quality<\/strong><\/h3>\n\n\n\n

Technical track records, specifically NDA\/BLA submission history and CRL rates, are objective indicators of regulatory execution capability. Biologics manufacturing experience is a distinct and essential competency for biologics programs, not a generic pharmaceutical management skill. Board composition affects portfolio prioritization quality. BD deal structure and historical deal economics are measurable signals of an organization’s ability to create value through licensing.<\/p>\n\n\n\n

\n\n\n\n

Competitive Landscape Analysis: Reading the Patent Cliff Before It Drops<\/h2>\n\n\n\n

Competitive intelligence in pharma is not a one-time diligence activity. It requires continuous monitoring across five vectors: competitor patent estates, clinical trial registries, regulatory submission status, payer and formulary dynamics, and business development activity.<\/p>\n\n\n\n

Mapping the Competitive Patent Estate<\/strong><\/h3>\n\n\n\n

An IP team evaluating a drug’s competitive position needs to map not just its own company’s patents but every patent held by active competitors covering the same mechanism of action, disease indication, or patient population. The relevant patent types to track include composition-of-matter patents, method-of-treatment patents covering the indication, formulation patents covering the delivery system, and device patents if the drug requires a specific delivery device.<\/p>\n\n\n\n

The Orange Book and Purple Book are the primary U.S. registries for listed drug patents. The Orange Book covers small-molecule drugs approved through the NDA pathway; the Purple Book covers biologics and biosimilars. Both are searchable by drug name, active ingredient, and application number. However, neither covers the full relevant patent universe: method-of-treatment patents are often not Orange Book-listed, and process patents covering manufacturing are filed outside the drug approval framework entirely.<\/p>\n\n\n\n

For complete competitive patent mapping, IP teams use a combination of Orange Book\/Purple Book searches, USPTO patent database queries by company assignee and relevant CPC codes, and EPO and WIPO databases for international coverage. Commercial databases like Derwent Innovation, PatSnap, and Cipher (from Clarivate) provide citation mapping and patent family analysis that identifies related applications across jurisdictions.<\/p>\n\n\n\n

Evergreening Tactics: The Technology Roadmap<\/strong><\/h3>\n\n\n\n

The pharmaceutical industry’s evergreening toolkit has expanded significantly over the past 20 years. The tactics are well-documented individually but are most analytically useful when understood as a coordinated multi-year IP strategy. The complete evergreening roadmap for a major branded drug typically includes the following components deployed in sequence.<\/p>\n\n\n\n

Phase 1 begins four to six years before the composition-of-matter patent expiry. The manufacturer files new patents on the active metabolite of the drug, on polymorphic crystal forms with improved stability, on salts with different solubility profiles, and on specific particle size ranges required for the approved formulation. These filings are legitimate patent applications but are calibrated to create obstacles for generic manufacturers who must design around or challenge them.<\/p>\n\n\n\n

Phase 2, typically two to three years before expiry, involves the 505(b)(2) reformulation strategy described earlier. The manufacturer advances the reformulated product through the NDA process and begins commercial transition, supported by marketing programs that shift prescribing to the new product.<\/p>\n\n\n\n

Phase 3, concurrent with or immediately following the composition-of-matter patent expiry, involves the authorized generic strategy, where the branded manufacturer licenses its own ANDA to a generic partner and captures generic market revenue without the standard 80-90% erosion in net revenue per unit. This strategy is most effective when the brand holds or licenses the first-filer exclusivity, allowing it to participate in the 180-day exclusivity period granted to the first Paragraph IV ANDA filer.<\/p>\n\n\n\n

Phase 4, applicable to combination products, involves patent protection on the fixed-dose combination formulation, which may have a separate clinical differentiation argument (improved adherence, simplified dosing) and a fresh patent term.<\/p>\n\n\n\n

Investment Strategy: When analyzing a brand facing patent expiry in the next three to five years, map which phases of the evergreening roadmap the manufacturer has already deployed and which remain available. A brand that has already exhausted multiple evergreening options, has no active 505(b)(2) in late-stage development, and faces a dense Paragraph IV filing landscape from multiple generic ANDA filers is at peak patent cliff exposure. One that still has a 505(b)(2) reformulation in Phase III and an authorized generic arrangement pending has meaningfully better revenue durability.<\/strong><\/p>\n\n\n\n

Paragraph IV Litigation and the 30-Month Stay<\/strong><\/h3>\n\n\n\n

When a generic manufacturer files an ANDA with a Paragraph IV certification, it asserts that the relevant Orange Book-listed patents are invalid, unenforceable, or not infringed by the generic. The branded manufacturer has 45 days to file suit; doing so triggers an automatic 30-month stay of FDA approval for the generic, providing a litigation window.<\/p>\n\n\n\n

The commercial value of the 30-month stay depends on two factors: the likelihood that the branded manufacturer prevails in the patent litigation, and the financial leverage it creates for settlement negotiations. Settlements involving authorized generic agreements, market entry date agreements, or royalty arrangements are common outcomes that give both parties certainty. From the branded side, a settlement that grants generic market entry 12 months before the composition-of-matter patent expiry with an authorized generic arrangement can be financially superior to winning the litigation, which merely delays generic entry to the patent expiry date.<\/p>\n\n\n\n

Analysts tracking Paragraph IV certifications by therapeutic area and company get advance warning of competitive pressure well before market dynamics shift. The first Paragraph IV filer’s 180-day exclusivity, the settlement economics, and the resulting entry timeline are all signals that can be modeled into forward revenue assumptions years before they hit quarterly numbers.<\/p>\n\n\n\n

Key Takeaways: Competitive Landscape<\/strong><\/h3>\n\n\n\n

Patent mapping requires coverage across composition, method-of-treatment, formulation, process, and device patents, not just Orange Book listings. Evergreening is a phased multi-year strategy whose remaining runway can be assessed by tracking which phases have already been executed. Paragraph IV filings are public signals of competitive pressure with defined legal timelines that allow advance revenue modeling. The first Paragraph IV filer’s 180-day exclusivity creates a settlement negotiation structure that often resolves into authorized generic economics favorable to both parties.<\/p>\n\n\n\n

\n\n\n\n

Brand Reputation and ESG: The Metrics Institutional Allocators Now Require<\/h2>\n\n\n\n

Brand reputation in pharmaceuticals has a specific structural role that differs from consumer goods: it influences not just end-consumer preference but prescriber behavior, payer trust, regulatory agency goodwill, and employee recruitment in a highly competitive talent market.<\/p>\n\n\n\n

Reputational Risk and Market Capitalization<\/strong><\/h3>\n\n\n\n

Pharmaceutical companies occupy a reputational landscape shaped by drug pricing controversies, safety recalls, clinical data manipulation allegations, and access-to-medicine debates. The pricing debate is financially material. Companies whose drug pricing practices become the subject of Congressional hearings or sustained media attention face multiple headwinds simultaneously: political pressure to reduce list prices (which accelerates gross-to-net deterioration), institutional investor pressure (ESG screening filters exclude companies with egregious pricing practices at a growing number of large funds), and prescriber behavior changes in cases where public controversy reaches clinical communities.<\/p>\n\n\n\n

Tracking reputational risk requires monitoring sources that precede financial impact by months: congressional testimony schedules, CMS price negotiation selection criteria, investigative journalism targets, and academic publication patterns on drug pricing and access.<\/p>\n\n\n\n

ESG Scoring in Pharmaceutical Investment Decisions<\/strong><\/h3>\n\n\n\n

Institutional allocators managing public equity mandates increasingly apply ESG screens to pharmaceutical holdings. The specific ESG dimensions most relevant to pharma investment analysis are access to medicines (tiered pricing programs, generic licensing agreements in lower-income countries, IP pledge participation), clinical trial diversity and inclusion practices, environmental metrics for manufacturing operations (solvent waste, water use, carbon emissions in API synthesis), and governance structures around executive compensation tied to non-financial metrics.<\/p>\n\n\n\n

The challenge for pharmaceutical ESG assessment is that current ESG frameworks apply inconsistent weights across E, S, and G dimensions. Many major ESG rating providers score pharmaceutical companies primarily on governance and environmental metrics, where data is relatively standardized, while underweighting social metrics like access to medicines, where data is scarce and methodologies are less mature. This creates a divergence between ESG scores and the social impact indicators that the investor community nominally prioritizes.<\/p>\n\n\n\n

For portfolio managers, the practical implication is that ESG scores from major providers (MSCI, Sustainalytics, ISS) are useful for screening but should not substitute for first-party analysis on the social dimension. Companies with strong access-to-medicine programs, transparent trial diversity reporting, and executive compensation structures that include patient outcome metrics tend to have more durable stakeholder relationships, which in turn reduces the probability of regulatory friction, Congressional targeting, and consumer boycotts.<\/p>\n\n\n\n

Investment Strategy: ESG factors in pharma are not solely a values-alignment consideration. They are a risk mitigation variable. Companies with poor drug pricing practices, low clinical trial diversity, and weak access-to-medicine commitments face concentrated tail risks: Congressional price controls, formulary exclusion by ESG-screened PBMs, and talent recruitment disadvantages in the scientific workforce. These are quantifiable risk factors, not soft metrics. Build them into probability adjustments on political\/regulatory risk scenarios.<\/strong><\/p>\n\n\n\n

Key Takeaways: Brand Reputation and ESG<\/strong><\/h3>\n\n\n\n

Reputational risk in pharma creates multiple simultaneous financial exposures, not just consumer preference effects. ESG scoring methodologies underweight social metrics relative to environmental and governance, which means first-party analysis of access-to-medicine and trial diversity is required for accurate ESG risk assessment. ESG factors are quantifiable risk variables, not qualitative overlays.<\/p>\n\n\n\n

\n\n\n\n

Litigation Risk and Paragraph IV Dynamics <\/h2>\n\n\n\n

Patent litigation is a defining feature of pharmaceutical competitive dynamics and belongs in every investment thesis for branded drugs with meaningful revenue.<\/p>\n\n\n\n

The Full Litigation Taxonomy<\/strong><\/h3>\n\n\n\n

The Paragraph IV certification and 30-month stay process is the most commonly discussed form of pharmaceutical patent litigation, but it is one of four distinct litigation categories that affect pharmaceutical IP valuation.<\/p>\n\n\n\n

Inter partes review (IPR) petitions at the Patent Trial and Appeal Board (PTAB) allow third parties (including generic manufacturers) to challenge patent validity on grounds of prior art. PTAB proceedings are faster and cheaper than district court litigation, and institution rates for pharmaceutical patent IPR petitions run above 60%. A successful IPR can invalidate a core patent without a Paragraph IV filing, and can be filed while a 30-month stay is running in parallel, creating a dual-track challenge strategy that branded manufacturers must defend on two fronts simultaneously.<\/p>\n\n\n\n

Patent interference and derivation proceedings address priority disputes between applicants. These are less common in modern prosecution since the U.S. moved to a first-inventor-to-file system under the America Invents Act, but legacy first-to-invent patents (filed before March 2013) can still face interference.<\/p>\n\n\n\n

Inequitable conduct allegations claim that the patent applicant withheld material prior art or made false statements during prosecution. A successful inequitable conduct finding renders the patent unenforceable, which is a worse outcome for the patentee than invalidity because it typically cannot be cured by divisional or continuation filings.<\/p>\n\n\n\n

The Settlement Landscape and Pay-for-Delay Risk<\/strong><\/h3>\n\n\n\n

Pay-for-delay (reverse payment) settlements, where the branded manufacturer pays the generic challenger to delay market entry, remain legally permissible under the FTC v. Actavis framework but are subject to antitrust challenge if the payment is large and unexplained by conventional litigation considerations. The FTC monitors this landscape actively, and settlements involving substantial cash payments to generic challengers generate regulatory scrutiny that creates its own litigation exposure.<\/p>\n\n\n\n

The structured settlement that most effectively balances legal and commercial risk gives the generic manufacturer an authorized license to enter the market at a specific date, often one to three years before the patent expiry, without a cash payment, in exchange for the generic ceasing its patent challenge. Both parties gain certainty without the antitrust exposure of a reverse payment.<\/p>\n\n\n\n

Investment Strategy: Track all Paragraph IV certifications filed against a portfolio company’s drugs as a leading indicator. ANDA filing data is publicly available through the FDA ANDA approval database and through commercial services like DrugPatentWatch. A drug receiving its first Paragraph IV filing with eight or more years remaining on the composition-of-matter patent has a different risk profile than one filed 18 months before expiry. For the former, the litigation outcome and any resulting settlement terms will define the effective exclusivity end date.<\/strong><\/p>\n\n\n\n

\n\n\n\n

Supply Chain Resilience as an Investable Variable <\/h2>\n\n\n\n

Supply chain disruption became a visible pharmaceutical investment risk during the COVID-19 pandemic, but it is a chronic structural variable, not an acute crisis. Single-source API dependencies, geographic concentration of active ingredient manufacturing, and cold chain requirements for biologics create specific, quantifiable risk profiles that belong in investment models.<\/p>\n\n\n\n

API Sourcing Concentration Risk<\/strong><\/h3>\n\n\n\n

A substantial proportion of API for small-molecule drugs sold in the United States is manufactured in India and China. The FDA’s Drug Shortage database and recent Section 232 investigations have documented the extent of geographic concentration in specific therapeutic categories, including antibiotics (where Chinese API production is dominant) and generic cardiovascular drugs.<\/p>\n\n\n\n

For branded manufacturers, API sourcing concentration is partly a CMC regulatory issue: FDA manufacturing facility approvals and import alert status are public information that signals supply continuity risk. A drug with a single FDA-approved API manufacturing site in a jurisdiction with a history of import alerts, inspection findings, or geopolitical friction is carrying concentrated supply risk that a dual-source or domestic-source program would mitigate.<\/p>\n\n\n\n

For investors, the signal to monitor is the number of FDA-approved API sites for a drug’s active ingredients. Drugs with two or more approved sites have meaningfully better supply continuity profiles than single-source programs, regardless of the manufacturer’s operational quality track record.<\/p>\n\n\n\n

Biologic Manufacturing Complexity<\/strong><\/h3>\n\n\n\n

Biologics manufacturing carries a distinctly different risk profile than small-molecule API synthesis. Cell line development, fermentation process validation, and fill-and-finish aseptic manufacturing are capital-intensive, time-consuming, and difficult to transfer between facilities without comparability studies. A biologic manufacturer that loses a batch due to contamination, or that sees fermentation yields decline due to cell line drift, faces a supply disruption that cannot be resolved by switching to a backup supplier in the way a small-molecule manufacturer can.<\/p>\n\n\n\n

Contract development and manufacturing organizations (CDMOs) have become the primary outsourcing partner for mid-size and smaller biologics companies without in-house manufacturing. The commercial dynamics of the CDMO market, including capacity constraints, lead times for new batch manufacturing slots, and the regulatory complexity of adding a CDMO as an approved manufacturing site in an existing BLA, are supply chain variables that directly affect launch timing and commercial continuity for biologics programs.<\/p>\n\n\n\n

\n\n\n\n

The Political and Regulatory Macro Layer: IRA, PDABs, and Executive Orders<\/h2>\n\n\n\n

The political environment for pharmaceutical pricing has shifted materially since 2021 and continues to evolve in ways that affect specific assets and therapeutic categories differently.<\/p>\n\n\n\n

The Inflation Reduction Act: Full Modeling Framework<\/strong><\/h3>\n\n\n\n

The IRA’s three pricing provisions require explicit modeling: the Medicare Drug Price Negotiation Program, the inflation rebate requirement, and the out-of-pocket cap for Part D beneficiaries.<\/p>\n\n\n\n

The Drug Price Negotiation Program’s selection logic follows a specific algorithm. CMS selects drugs with the highest total Medicare Part D expenditure among those lacking generic or biosimilar competition, after a nine-year small-molecule or thirteen-year biologic post-approval period. For each drug selected, CMS negotiates a Maximum Fair Price using a formula that references domestic and international price comparisons, evidence of clinical benefit, unmet medical need, and development costs. The Maximum Fair Price must be at least 25% below the 2021 non-federal average manufacturer price for the drug.<\/p>\n\n\n\n

The inflation rebate provision penalizes manufacturers whose price increases exceed the rate of inflation. Manufacturers pay the excess price increase back to CMS as a rebate, which reduces the financial incentive for annual price increases above CPI. This provision changes the gross-to-net dynamics for drugs still in their commercial exclusivity period but not yet subject to negotiation.<\/p>\n\n\n\n

For modeling purposes, analysts should classify each portfolio drug into one of four IRA exposure categories: currently selected for negotiation, eligible within three years based on expenditure ranking, potentially eligible beyond three years, or not eligible due to generic\/biosimilar competition or insufficient Medicare expenditure. Each category carries a different revenue impact probability distribution.<\/p>\n\n\n\n

Prescription Drug Affordability Boards<\/strong><\/h3>\n\n\n\n

Several states have established PDABs with authority to set upper payment limits (UPLs) on drugs for state-regulated health plans, Medicaid, and public employee programs. Maryland’s PDAB was among the first to exercise this authority, targeting high-cost drugs with limited therapeutic alternatives. The legal landscape for PDAB authority is contested, with industry litigation arguing that state UPLs conflict with the federal ERISA preemption framework for self-insured plans.<\/p>\n\n\n\n

For drugs with significant exposure to state-regulated commercial markets or public employee programs, PDAB activity is an incremental pricing constraint that supplements IRA negotiation risk. The combined effect of federal Medicare negotiation and state PDAB upper payment limits, if both apply to a given drug, can create a pricing ceiling from two directions simultaneously.<\/p>\n\n\n\n

Investment Strategy: Every branded drug with Medicare revenue above $200M annually and without generic\/biosimilar competition within its regulatory exclusivity period should have an explicit IRA scenario modeled in the forward revenue assumptions. The base case should include the probability-weighted revenue impact of negotiation selection, the expected magnitude of the Maximum Fair Price discount, and the timing of when the MFP takes effect. PDAB exposure adds a secondary state-level pricing constraint that affects the commercial market, not Medicare, and should be modeled separately for drugs in states with active PDAB programs.<\/strong><\/p>\n\n\n\n

\n\n\n\n

Building the Composite Investment Framework<\/h2>\n\n\n\n

The ten factors above do not operate independently. Their interactions are what create the full risk and opportunity profile of a pharmaceutical investment. The composite analytical framework integrates them across five dimensions.<\/p>\n\n\n\n

The IP Durability Score<\/strong><\/h3>\n\n\n\n

IP durability is a function of: total years of effective exclusivity remaining (patent expiry plus any regulatory exclusivity extension, minus any live Paragraph IV challenges that could truncate it), the breadth of the patent estate (whether composition, formulation, method-of-treatment, process, and device claims are all present), and the remaining evergreening roadmap (which phases have been executed, which remain available).<\/p>\n\n\n\n

A composite IP durability score for a given drug, built from these inputs, is more predictive of revenue durability than any single patent expiry date. It can be expressed as a probabilistic range: in the bear case (Paragraph IV challenge succeeds, no evergreening available), generic entry occurs in X years. In the base case (patent litigation resolves via authorized generic settlement), entry occurs in Y years. In the bull case (505(b)(2) transition successful, all challenges defeated), effective exclusivity extends to Z years.<\/p>\n\n\n\n

The Commercial Execution Score<\/strong><\/h3>\n\n\n\n

Market access quality, management track record, and payer formulary positioning combine into a commercial execution assessment. Specific indicators: formulary tier status at the top five commercial payers, prior authorization burden relative to therapeutic competitors, HTA outcome status in major markets, and management’s prior commercialization experience in the same therapeutic area and price tier.<\/p>\n\n\n\n

The Pipeline Risk-Adjusted Value<\/strong><\/h3>\n\n\n\n

Clinical stage assets should be valued using probability-weighted NPV with company-specific rather than industry-average success rates, where the company’s track record and trial design quality support the adjustment. Phase II assets with validated biomarkers and adaptive design elements warrant higher Phase II-to-Phase III transition probabilities than unvalidated programs in the same disease area.<\/p>\n\n\n\n

The Political\/Regulatory Scenario Set<\/strong><\/h3>\n\n\n\n

Each major asset’s revenue model should carry four scenario assumptions: base (current regulatory environment), IRA acceleration (faster or broader Medicare negotiation implementation), state pricing intervention (PDAB UPLs in additional states), and trade\/supply disruption (API sourcing constraints or tariff-driven cost increases). The probability-weighted revenue across these scenarios gives a more complete expected value than modeling only the base case.<\/p>\n\n\n\n

The ESG and Reputation Tail Risk<\/strong><\/h3>\n\n\n\n

A tail risk probability adjustment on revenue and multiples, reflecting the probability of a Congressional pricing controversy, regulatory inspection finding, or major clinical safety issue based on available public information. Not a zero or a rounding error, but a 5-15% probability adjustment on valuation multiple in cases where any of these risk factors are elevated.<\/p>\n\n\n\n

Key Takeaways: The Composite Framework<\/strong><\/h3>\n\n\n\n

No single non-patent factor fully determines pharmaceutical investment outcomes. The analyst who can build and update a composite framework, integrating IP durability, commercial execution quality, pipeline probability, political\/regulatory scenario exposure, and ESG tail risk, into a single probability-weighted valuation, is doing the work that justifies institutional returns in this sector. Patent expiry dates are the starting coordinate. These ten factors are the map.<\/p>\n\n\n\n

\n\n\n\n

About This Analysis<\/h2>\n\n\n\n

This pillar page covers regulatory exclusivity (orphan drug designation, 505(b)(2), and biosimilar interchangeability), market access and reimbursement (including the IRA and HTA mechanics), clinical trial probability and biomarker strategy, management team competency indicators, competitive patent landscape and evergreening tactics, brand reputation and ESG screening, Paragraph IV litigation dynamics, supply chain resilience, and the macro political\/regulatory layer. It is intended as a reference document for IP teams, portfolio managers, R&D leads, and institutional investors conducting pharmaceutical company analysis.<\/p>\n\n\n\n

Data referenced throughout draws on publicly available FDA databases, SEC filings, CMS program documentation, and published academic literature on clinical trial success rates and pharmaceutical economics. <\/p>\n\n\n\n

\n\n\n\n

For patent expiration data, Paragraph IV filing tracking, biosimilar pipeline analysis, and Orange Book monitoring, DrugPatentWatch provides the primary commercial database infrastructure referenced throughout this analysis.<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"

Why Patents Are the Wrong Starting Point Most analysts open a pharma investment thesis by pulling Orange Book listings and […]<\/p>\n","protected":false},"author":1,"featured_media":35157,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_lmt_disableupdate":"","_lmt_disable":"","site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[87,10],"tags":[],"class_list":["post-11018","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-customer-success","category-insights"],"modified_by":"DrugPatentWatch","_links":{"self":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts\/11018","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/comments?post=11018"}],"version-history":[{"count":3,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts\/11018\/revisions"}],"predecessor-version":[{"id":37741,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts\/11018\/revisions\/37741"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/media\/35157"}],"wp:attachment":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/media?parent=11018"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/categories?post=11018"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/tags?post=11018"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}